Raji-Luc2 from ATCC

Product Specs
ItemRaji-Luc2
CompanyATCC
Price $1,285.00Supplier Page View Company Product Page
Catalog NumberCCL-86-LUC2
TypeCell Biology
ApplicationsExcellent signal/background ratio and stable luciferase expression make this cell line ideal for in vitro study of CD19 specific CAR-T cells. This target cell line can also be incorporated in other assessments such as ADCC and natural killer (NK) cell cytotoxicity assays
Quantity>= 1.0 x 10^6
Research AreaImmuno-oncology, Assay development, Cancer research, Cell and gene therapy (CGT) development
Cell TypeB lymphocyte
GenderMale
Age11 years
Cell LineRaji-Luc2
DiseaseBurkitts Lymphoma
SpeciesHomo sapiens
Volume1.0 mL

Add to Compare List

ATCC

10801 University Boulevard

Manassas, Virginia 20110-2209

United States

Phone: (703) 365-2700
Fax: (703) 365-2701

Company Profile

Website: http://www.atcc.org

(1) Rapid receptor internalization potentiates CD7-targeted lipid nanoparticles for efficient mRNA delivery to T cells and in vivo CAR T-cell engineeringbioRxivJanuary 30, 2026Jianhao Zeng, Tyler Ellis Papp, Awurama Akyianu, Alejandra Bahena, Lanfranco Leo, Faris Halilovic, Hamideh Parhizactivity, CAR T cells were then co-cultured with CD20-expressing, luciferase-labeled Raji cells (ATCC, cat# CCL-86-LUC2) at effector-to-target ratios of 1:1, 2:1, 5:1, and 10:1. 10,000 Raji cells in 50 μL of Raji cell medium

(2) Bio-functional hydrogel coated membranes to decrease T-cell exhaustion in manufacturing of CAR T-cellsFrontiers in ImmunologyJune 27, 2025Aida López Ruiz, Eric Slaughter, Kartik Bomb, Samantha L. Swedzinski, Paige J. LeValley, Zaining Yun, Jacob McCoskey, Kara Levine, Jonathan Steen, Joseph Almasian, et al.of activation, transduction, and expansion typically used during CAR T-cell production. Raji-Luc2 (CCL-86-LUC2, ATCC, Manassas, VA) were used as target cells for the experiments, and impedance was used to determine

(3) Comparable efficacy of oral bendamustine versus intravenous administration in treating hematologic malignanciesCancer Chemotherapy and PharmacologySeptember 1, 2024Megan J. Cracchiolo, Lisa Davis, Andrew P. Matiatos, Dan W. Davini, Muhammad Husnain, Richard J. Simpson, Vasilios Voudouris, Emmanuel Katsanisusing GraphPad Prism 9 (La Jolla, CA, RRID:SCR_002798). Tumor models Raji-Luciferase (Raji-Luc, ATCC, CCL-86-LUC2, 70,059,299, RRID:CVCL_C9CV), MM.1s-Luc (Fenics Bio, CL-1617, 080721), and RS4;11-Luc (Fenics Bio, CL-1221)

(4) Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicityNature protocolsMarch 1, 2021Kiesgen S, Messinger JC, Chintala NK, Tano Z, Adusumilli PS.

(5) Driving CAR T-cells forwardNature reviews. Clinical oncologyJune 1, 2016Jackson HJ, Rafiq S, Brentjens RJ.

(6) CYTOLOGY OF BURKITT'S TUMOUR (AFRICAN LYMPHOMA)Lancet (London, England)February 1, 1964PULVERTAFT JV.

Be the First to Write a Review!

Description

ATCC

Citations (6)

Reviews

Raji-Luc2 from ATCC

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map